-
摘要: 随着免疫检查点抑制剂(ICI)在肿瘤患者中的广泛应用，免疫相关不良事件愈发受到关注。程序性细胞死亡蛋白-1(PD-1)和程序性细胞死亡配体-1(PD-L1)在人心肌细胞中表达，因此应用PD-1/PDL-1抑制剂的同时，可能会对心血管系统造成诸多不良反应。本文综述了PD-1/PD-L1抑制剂心血管毒性的最新流行病学证据、临床表现以及潜在的病理机制及目前的诊疗方法，以期为ICI毒性监测和制定治疗策略提供新的视角。
-
关键词:
- 免疫检查点抑制剂 /
- 心脏毒性 /
- 程序性细胞死亡蛋白-1 /
- 肿瘤免疫疗法
Abstract: With the wide application of immune checkpoint inhibitors(ICIs) in tumor patients, immune related adverse events have attracted more attention. PD-1 and PD-L1 are expressed in human cardiomyocytes, so the application of PD-1/PDL-1 inhibitors can cause many adverse reactions to the cardiovascular system. This review summarizes the latest epidemiological evidence on the cardiovascular toxicity of programmed cell death protein-1(PD-1)/programmed cell death ligand-1(PD-L1) inhibitors and the clinical manifestations, as well as the potential pathological mechanisms and current diagnosis and treatment strategies. These updates may provide a novel perspective for monitoring early toxicity and establishing appropriate treatment for patients with ICI-related cardiotoxicity. -
-
[1] Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions[J]. Mol Cancer, 2018, 17(1): 48. doi: 10.1186/s12943-018-0804-2
[2] Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations[J]. J Immunother Cancer, 2018, 6(1): 8. doi: 10.1186/s40425-018-0316-z
[3] Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs[J]. JAMA Netw Open, 2019, 2(5): e192535. doi: 10.1001/jamanetworkopen.2019.2535
[4] Weyand CM, Berry GJ, Goronzy JJ. The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease[J]. J Leukoc Biol, 2018, 103(3): 565-575. doi: 10.1189/jlb.3MA0717-283
[5] Dummer R, Ascierto PA, Nathan P, et al. Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: a review[J]. JAMA Oncol, 2020, 20: 110. http://pubmed.ncbi.nlm.nih.gov/32970096/
[6] Leonetti A, Wever B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer[J]. Drug Resist Updat, 2019, 46: 100644. doi: 10.1016/j.drup.2019.100644
[7] Atkins MB, Clark JI, Quinn DI. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions[J]. Ann Oncol, 2017, 28(7): 1484-1494. doi: 10.1093/annonc/mdx151
[8] Rossi C, Gravelle P, Decaup E, et al. Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma[J]. Oncoimmunology, 2019, 8(3): 1554175. doi: 10.1080/2162402X.2018.1554175
[9] Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290. doi: 10.1056/NEJMoa1712126
[10] Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. doi: 10.1001/jamaoncol.2018.3923
[11] Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. doi: 10.1056/NEJMra1703481
[12] Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors[J]. Cardiovasc Res, 2019, 115(5): 854-868. doi: 10.1093/cvr/cvz026
[13] Waliany S, Lee D, Witteles RM, et al. Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure[J]. Annu Rev Pharmacol Toxicol, 2021, 61: 113-134. doi: 10.1146/annurev-pharmtox-010919-023451
[14] Lyon AR, Yousaf N, Battisti N, et al. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol, 2018, 19(9): e447-e458. doi: 10.1016/S1470-2045(18)30457-1
[15] 陈炳秀, 吴代琴, 吴立荣, 等. 咽喉癌化疗后免疫检查点抑制剂相关心肌炎1例[J]. 临床心血管病杂志, 2023, 39(1): 76-80. doi: 10.13201/j.issn.1001-1439.2023.01.014 https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2023.01.014
[16] Mir H, Alhussein M, Alrashidi S, et al. Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area[J]. Can J Cardiol, 2018, 34(8): 1059-1068. doi: 10.1016/j.cjca.2018.03.012
[17] Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol, 2018, 71(16): 1755-1764. doi: 10.1016/j.jacc.2018.02.037
[18] Han D, Dong J, Li H, et al. Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review[J]. Medicine(Baltimore), 2020, 99(5): e18701. http://pubmed.ncbi.nlm.nih.gov/32000374/
[19] Dolladille C, Ederhy S, Allouche S, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors[J]. J Immunother Cancer, 2020, 8(1): 110. http://www.socolar.com/Article/Index?aid=200259983067&jid=200000133824
[20] Chen DY, Huang WK, Chien-Chia Wu V, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology[J]. J Formos Med Assoc, 2020, 119(10): 1461-1475. doi: 10.1016/j.jfma.2019.07.025
[21] 黄磊, 解玉泉. 免疫检查点抑制剂相关性心肌炎的研究进展[J]. 临床心血管病杂志, 2020, 36(5): 410-414. doi: 10.13201/j.issn.1001-1439.2020.05.004
[22] 夏云龙, 刘飞. 抗肿瘤药物相关高血压的研究进展[J]. 临床心血管病杂志, 2022, 38(8): 609-613. doi: 10.13201/j.issn.1001-1439.2022.08.003 https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.08.003
[23] Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment[J]. J Am Heart Assoc, 2020, 9(2): e013757. doi: 10.1161/JAHA.119.013757
[24] Ala CK, Klein AL, Moslehi JJ. Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management[J]. Curr Cardiol Rep, 2019, 21(12): 156. doi: 10.1007/s11886-019-1225-6
[25] Guo X, Wang H, Zhou J, et al. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity[J]. Thorac Cancer, 2020, 11(2): 475-480. doi: 10.1111/1759-7714.13250
[26] Behravesh S, Shomali N, Danbaran GR, et al. Cardiotoxicity of immune checkpoint inhibitors: An updated review[J]. Biotechnol Appl Biochem, 2020, 20: 110.
[27] Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells[J]. Immunol Cell Biol, 2018, 96(1): 21-33. doi: 10.1111/imcb.1003
[28] Varricchi G, Marone G, Mercurio V, et al. Immune checkpoint inhibitors and cardiac toxicity: an emerging issue[J]. Curr Med Chem, 2018, 25(11): 1327-1339. doi: 10.2174/0929867324666170407125017
[29] Planes-Laine G, Rochigneux P, Bertucci F, et al. PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging. a literature review[J]. Cancers(Basel), 2019, 11(7): 110. http://pubmed.ncbi.nlm.nih.gov/31336685/
[30] Danbaran GR, Aslani S, Sharafkandi N, et al. How microRNAs affect the PD-L1 and its synthetic pathway in cancer[J]. Int Immunopharmacol, 2020, 84: 106594. doi: 10.1016/j.intimp.2020.106594
[31] Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016, 375(18): 1749-1755. doi: 10.1056/NEJMoa1609214
[32] Khunger A, Battel L, Wadhawan A, et al. New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity[J]. Curr Oncol Rep, 2020, 22(7): 65. doi: 10.1007/s11912-020-00925-8
[33] Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study[J]. Lancet Oncol, 2018, 19(12): 1579-1589. doi: 10.1016/S1470-2045(18)30608-9
[34] Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors[J]. ESMO Open, 2017, 2(4): e000247. doi: 10.1136/esmoopen-2017-000247
[35] Varricchi G, Galdiero MR, Tocchetti CG. Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology[J]. Circulation, 2017, 136(21): 1989-1992. doi: 10.1161/CIRCULATIONAHA.117.029626
[36] Grabie N, Lichtman AH, Padera R. T cell checkpoint regulators in the heart[J]. Cardiovasc Res, 2019, 115(5): 869-877. doi: 10.1093/cvr/cvz025
[37] Ji C, Roy MD, Golas J, et al. Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors[J]. Clin Cancer Res, 2019, 25(15): 4735-4748. doi: 10.1158/1078-0432.CCR-18-4083
[38] Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia[J]. Nat Rev Cardiol, 2020, 17(8): 474-502.
[39] Seijkens T, van Tiel CM, Kusters P, et al. Targeting CD40-Induced TRAF6 signaling in macrophages reduces atherosclerosis[J]. J Am Coll Cardiol, 2018, 71(5): 527-542. doi: 10.1016/j.jacc.2017.11.055
[40] Newman JL, Stone JR. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis[J]. Cardiovasc Pathol, 2019, 43: 107148. http://pubmed.ncbi.nlm.nih.gov/31518915/
[41] Pohl J, Mincu RI, Mrotzek SM, et al. ECG Changes in melanoma patients undergoing cancer therapy-data from the ECoR Registry[J]. J Clin Med, 2020, 9(7): 110. http://www.socolar.com/Article/Index?aid=100082970835&jid=100000036339
[42] Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018.391(10124): 933. http://middleeast.thelancet.com/article/S0140673618305336/pdf
[43] Chen Q, Huang DS, Zhang LW, et al. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma[J]. Clin Toxicol(Phila), 2018, 56(7): 667-671. http://dx.doi.org/10.1080/15563650.2017.1401079
[44] Zhou YW, Zhu YJ, Wang MN, et al. Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management[J]. Front Pharmacol, 2019, 10: 1350. http://doc.paperpass.com/foreign/rgArti2019165479099.html
[45] Liu Y, Wu W. Cardiovascular immune-related adverse events: Evaluation, diagnosis and management[J]. Asia Pac J Clin Oncol, 2020, 16(4): 232-240. http://doc.paperpass.com/foreign/rgArti2020284002455.html
[46] Totzeck M, Schuler M, Stuschke M, et al. Cardio-oncology-strategies for management of cancer-therapy related cardiovascular disease[J]. Int J Cardiol, 2019, 280: 163-175. http://pubmed.ncbi.nlm.nih.gov/30661849/
[47] Pirozzi F, Poto R, Aran L, et al. Cardiovascular toxicity of immune checkpoint inhibitors: clinical risk factors[J]. Curr Oncol Rep, 2021, 23(2): 13. http://www.xueshufan.com/publication/3120763292
[48] Zhang JC, Chen WD, Alvarez JB, et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity[J]. Acta Pharmacol Sin, 2018, 39(11): 1693-1698. http://www.ncbi.nlm.nih.gov/pubmed/29991709
[49] Pudil R, Mueller C, Čelutkien J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology[J]. Eur J Heart Fail, 2020, 22(11): 1966-1983. http://www.nstl.gov.cn/paper_detail.html?id=ed4c0828861fb7bdda5ede3095fb1481
[50] Asnani A. Cardiotoxicity of immunotherapy: incidence, diagnosis, and management[J]. Curr Oncol Rep, 2018, 20(6): 44. http://link.springer.com/content/pdf/10.1007%2Fs11912-018-0690-1.pdf
[51] Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis[J]. Oncologist, 2018, 23(8): 879-886. http://www.sciencedirect.com/science/article/pii/S0140673618305336
[52] Stein-Merlob AF, Rothberg MV, Holman P, et al. Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy: diagnostic and management challenges and strategies[J]. Curr Cardiol Rep, 2021, 23(3): 11. http://pubmed.ncbi.nlm.nih.gov/33802788/
[53] Čelutkien J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association(HFA), the European Association of Cardiovascular Imaging(EACVI)and the Cardio-Oncology Council of the European Society of Cardiology(ESC)[J]. Eur J Heart Fail, 2020, 22(9): 1504-1524. http://www.nstl.gov.cn/paper_detail.html?id=ed4c0828861fb7bdda5ede3095fb1481
-
计量
- 文章访问数: 1648
- PDF下载数: 1750
- 施引文献: 0
下载: